These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 34586000)

  • 41. Hyperviscosity syndrome in splenic marginal zone lymphoma.
    Daniel R; Chan RY
    Blood; 2018 Oct; 132(15):1627. PubMed ID: 30309878
    [No Abstract]   [Full Text] [Related]  

  • 42. Constitutive expression of the AP-1 transcription factors c-jun, junD, junB, and c-fos and the marginal zone B-cell transcription factor Notch2 in splenic marginal zone lymphoma.
    Trøen G; Nygaard V; Jenssen TK; Ikonomou IM; Tierens A; Matutes E; Gruszka-Westwood A; Catovsky D; Myklebost O; Lauritzsen G; Hovig E; Delabie J
    J Mol Diagn; 2004 Nov; 6(4):297-307. PubMed ID: 15507668
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Molecular heterogeneity of splenic marginal zone lymphomas: analysis of mutations in the 5' non-coding region of the bcl-6 gene.
    Mateo MS; Mollejo M; Villuendas R; Algara P; Sanchez-Beato M; Martínez P; Piris MA
    Leukemia; 2001 Apr; 15(4):628-34. PubMed ID: 11368366
    [TBL] [Abstract][Full Text] [Related]  

  • 44. A deep molecular response of splenic marginal zone lymphoma to front-line checkpoint blockade.
    Miller PG; Sperling AS; Gibson CJ; Pozdnyakova O; Wong WJ; Manos MP; Buchbinder EI; Hodi FS; Ebert BL; Davids MS
    Haematologica; 2021 Feb; 106(2):651-654. PubMed ID: 33054119
    [No Abstract]   [Full Text] [Related]  

  • 45. Efficacy of bendamustine and rituximab in splenic marginal zone lymphoma: results from the phase II BRISMA/IELSG36 study.
    Iannitto E; Bellei M; Amorim S; Ferreri AJM; Marcheselli L; Cesaretti M; Haioun C; Mancuso S; Bouabdallah K; Gressin R; Tripodo C; Traverse-Glehen A; Baseggio L; Zupo S; Stelitano C; Castagnari B; Patti C; Alvarez I; Liberati AM; Merli M; Gini G; Cabras MG; Dupuis J; Tessoulin B; Perrot A; Re F; Palombi F; Gulino A; Zucca E; Federico M; Thieblemont C
    Br J Haematol; 2018 Dec; 183(5):755-765. PubMed ID: 30407629
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Successful rechallenge of rituximab following severe rituximab-induced acute thrombocytopenia in a patient with splenic marginal zone lymphoma.
    Robinson AC; Nachar VR
    J Oncol Pharm Pract; 2020 Jul; 26(5):1248-1253. PubMed ID: 31766968
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Genetic and phenotypic attributes of splenic marginal zone lymphoma.
    Bonfiglio F; Bruscaggin A; Guidetti F; Terzi di Bergamo L; Faderl M; Spina V; Condoluci A; Bonomini L; Forestieri G; Koch R; Piffaretti D; Pini K; Pirosa MC; Cittone MG; Arribas A; Lucioni M; Ghilardi G; Wu W; Arcaini L; Baptista MJ; Bastidas G; Bea S; Boldorini R; Broccoli A; Buehler MM; Canzonieri V; Cascione L; Ceriani L; Cogliatti S; Corradini P; Derenzini E; Devizzi L; Dietrich S; Elia AR; Facchetti F; Gaidano G; Garcia JF; Gerber B; Ghia P; Gomes da Silva M; Gritti G; Guidetti A; Hitz F; Inghirami G; Ladetto M; Lopez-Guillermo A; Lucchini E; Maiorana A; Marasca R; Matutes E; Meignin V; Merli M; Moccia A; Mollejo M; Montalban C; Novak U; Oscier DG; Passamonti F; Piazza F; Pizzolitto S; Rambaldi A; Sabattini E; Salles G; Santambrogio E; Scarfò L; Stathis A; Stüssi G; Geyer JT; Tapia G; Tarella C; Thieblemont C; Tousseyn T; Tucci A; Vanini G; Visco C; Vitolo U; Walewska R; Zaja F; Zenz T; Zinzani PL; Khiabanian H; Calcinotto A; Bertoni F; Bhagat G; Campo E; De Leval L; Dirnhofer S; Pileri SA; Piris MA; Traverse-Glehen A; Tzankov A; Paulli M; Ponzoni M; Mazzucchelli L; Cavalli F; Zucca E; Rossi D
    Blood; 2022 Feb; 139(5):732-747. PubMed ID: 34653238
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Primary nodal marginal zone lymphomas of splenic and MALT type.
    Campo E; Miquel R; Krenacs L; Sorbara L; Raffeld M; Jaffe ES
    Am J Surg Pathol; 1999 Jan; 23(1):59-68. PubMed ID: 9888704
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [Splenic marginal zone lymphoma].
    Mohamed S
    Pan Afr Med J; 2017; 26():111. PubMed ID: 28533834
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Clinical and diagnostic relevance of
    Campos-Martín Y; Martínez N; Martínez-López A; Cereceda L; Casado F; Algara P; Oscier D; Menarguez FJ; García JF; Piris MA; Mollejo M
    Haematologica; 2017 Aug; 102(8):e310-e312. PubMed ID: 28522570
    [No Abstract]   [Full Text] [Related]  

  • 51. Phenotype, Function, and Clinical Significance of CD26+ and CD161+Tregs in Splenic Marginal Zone Lymphoma.
    Tang X; Yang ZZ; Kim HJ; Anagnostou T; Yu Y; Wu X; Chen J; Krull JE; Wenzl K; Mondello P; Bhardwaj V; Wang J; Novak AJ; Ansell SM
    Clin Cancer Res; 2022 Oct; 28(19):4322-4335. PubMed ID: 35686915
    [TBL] [Abstract][Full Text] [Related]  

  • 52. A marginal zone pattern may be found in different varieties of non-Hodgkin's lymphoma: the morphology and immunohistology of splenic involvement by B-cell lymphomas simulating splenic marginal zone lymphoma.
    Piris MA; Mollejo M; Campo E; Menárguez J; Flores T; Isaacson PG
    Histopathology; 1998 Sep; 33(3):230-9. PubMed ID: 9777389
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Rituximab in a patient with splenic marginal zone lymphoma and acquired angioedema.
    Motosue MS; Howard MT; Butterfield JH
    Ann Allergy Asthma Immunol; 2016 May; 116(5):472-3. PubMed ID: 27017557
    [No Abstract]   [Full Text] [Related]  

  • 54. Epidermotropic CXCR3 positive marginal zone lymphoma: a distinctive clinical histopathological entity potentially originating in the skin; it does not always indicate splenic marginal zone lymphoma.
    Magro CM; Momtahen S; Coleman M; Grossman ME
    Dermatol Online J; 2019 Jul; 25(7):. PubMed ID: 31450275
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Splenic marginal-zone lymphoma: ontogeny and genetics.
    Baliakas P; Strefford JC; Bikos V; Parry M; Stamatopoulos K; Oscier D
    Leuk Lymphoma; 2015 Feb; 56(2):301-10. PubMed ID: 24798744
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Undetectable minimal residual disease is an independent prognostic factor in splenic marginal zone lymphoma.
    Lyu R; Wang T; Wang Y; Xiong W; Wang H; Yan Y; Wang Q; Liu W; An G; Huang W; Sui W; Xu Y; Zou D; Wang J; Qiu L; Yi S
    Br J Haematol; 2021 Sep; 194(5):862-869. PubMed ID: 34328213
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Characterization of immune exhaustion and suppression in the tumor microenvironment of splenic marginal zone lymphoma.
    Anagnostou T; Yang ZZ; Jalali S; Kim HJ; Larson DP; Tang X; Yu Y; Pritchett JC; Bisneto JV; Price-Troska TL; Mondello P; Novak AJ; Ansell SM
    Leukemia; 2023 Jul; 37(7):1485-1498. PubMed ID: 37117318
    [TBL] [Abstract][Full Text] [Related]  

  • 58. The NOTCH pathway is recurrently mutated in diffuse large B-cell lymphoma associated with hepatitis C virus infection.
    Arcaini L; Rossi D; Lucioni M; Nicola M; Bruscaggin A; Fiaccadori V; Riboni R; Ramponi A; Ferretti VV; Cresta S; Casaluci GM; Bonfichi M; Gotti M; Merli M; Maffi A; Arra M; Varettoni M; Rattotti S; Morello L; Guerrera ML; Sciarra R; Gaidano G; Cazzola M; Paulli M
    Haematologica; 2015 Feb; 100(2):246-52. PubMed ID: 25381127
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Distinctive clinical and histological features of Waldenström's macroglobulinemia and splenic marginal zone lymphoma.
    Arcaini L; Varettoni M; Boveri E; Orlandi E; Rattotti S; Zibellini S; Merli M; Lucioni M; Rizzi S; Gotti M; Morello L; Pascutto C; Paulli M
    Clin Lymphoma Myeloma Leuk; 2011 Feb; 11(1):103-5. PubMed ID: 21454204
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Usefulness of CD200 in the differential diagnosis of SDRPL, SMZL, and HCL.
    Favre R; Manzoni D; Traverse-Glehen A; Verney A; Jallades L; Callet-Bauchu E; Sujobert P; Salles G; Baseggio L
    Int J Lab Hematol; 2018 Aug; 40(4):e59-e62. PubMed ID: 29659173
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.